# The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

> **NCT01951729** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 15 (actual)

## Conditions studied

- Pre-diabetes

## Interventions

- **DRUG:** Control
- **DRUG:** Xenin-25 without atropine
- **DRUG:** GIP without atropine
- **DRUG:** Placebo with atropine
- **DRUG:** Xenin-25 with atropine
- **DRUG:** GIP with atropine
- **DRUG:** GIP plus Xenin-25 without atropine
- **DRUG:** GIP plus Xenin-25 with atropine

## Key facts

- **NCT ID:** NCT01951729
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-13
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01951729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01951729, "The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01951729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*